Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infections, Meningococcal Clear all

Conditions: Gonorrhoea
Interventions: Meningococcal Group B Vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease
Interventions: Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 56 Years and older
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Chandler, Arizona • Scottsdale, Arizona • Denver, Colorado + 9 more

Conditions: Meningitis, Meningococcemia
Interventions: Meningococcal polysaccharide diphtheria toxoid conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years to 6 Years
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Marietta, Georgia • Woodstock, Georgia • Bardstown, Kentucky + 9 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK134612; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 6 Years
Enrollment: 387 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 14
States / cities: Benton, Arkansas • Little Rock, Arkansas • Antioch, California + 10 more

Conditions: Acellular Pertussis, Tetanus, Diphtheria
Interventions: Boostrix®, Menactra™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 1,344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 24
States / cities: Chandler, Arizona • Little Rock, Arkansas • Fountain Valley, California + 18 more

Conditions: Meningitis, Meningococcal
Interventions: MenABCWY vaccine, Placebo; Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 11 Years to 14 Years
Enrollment: 305 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 24
States / cities: Birmingham, Alabama • Tucson, Arizona • Ventura, California + 19 more

Conditions: Meningococcal Meningitis, Meningococcal Infections
Interventions: NmVac4-A/C/Y/W-135-DT™; Biological
Lead sponsor: JN-International Medical Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: Meningitis, Meningococcal Infection
Interventions: MenACWY-CRM197, DTaP (Diptheria, Tetanus, Pertussis) Vaccine, Hib (Haemophilus influenza b) Vaccine, IPV (Inactivated Polio Vaccine) Vaccine, Pneumococcal conjugate Vaccine, MMR (Measles, Mumps, and Rubella) Vaccine, Varicella Vaccine, Hepatitis A Virus; Biological
Lead sponsor: Novartis; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 7,744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 130
States / cities: Birmingham, Alabama • Dothan, Alabama • Tuscon, Arizona + 107 more

Conditions: Infections, Meningococcal
Interventions: 4CMenB; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Meningococcal Meningitis
Interventions: MenACWY-CRM conjugate vaccine, Licensed comparator; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 32
States / cities: Birmingham, Alabama • Fremont, California • Fresno, California + 21 more

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 15 Years and older
Enrollment: 810 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Dothan, Alabama • Mesa, Arizona + 24 more

Conditions: Meningococcal Disease, Meningococcal Meningitis
Interventions: MenACWY-CRM, Routine Vaccines; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 55 Days to 89 Days
Enrollment: 751 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 37
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more

Conditions: Meningococcal Infection
Interventions: blood sampling, bivalent rLP2086; Procedure · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 698 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 36
States / cities: Chandler, Arizona • Huntington Beach, California • Paramount, California + 25 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal vaccine GSK 134612, Menactra®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 1,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Chandler, Arizona • Paramount, California • Sacramento, California + 19 more

Conditions: HIV Infections, Meningitis
Interventions: Quadrivalent meningococcal conjugate vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 24 Years
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 35
States / cities: Alhambra, California • Long Beach, California • Los Angeles, California + 25 more

Conditions: Meningitis, Meningococcal Infection
Interventions: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 15 Years to 23 Years
Enrollment: 145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 8
States / cities: Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more

Conditions: Meningococcal Infections, Meningococcal Meningitis
Interventions: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide, Menactra®: Polysaccharide Diphtheria Toxoid Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 56 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Scottsdale, Arizona • Bardstown, Kentucky • Albuquerque, New Mexico + 3 more

Conditions: Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions: Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 9 Months to 18 Months
Enrollment: 1,394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 56
States / cities: Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more

Conditions: Meningitis, Meningococcal
Interventions: rLP2086 vaccine, control; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 10 Years to 25 Years
Enrollment: 5,715 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 39
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more

Conditions: Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication, Satisfaction
Interventions: AFIX Only, AFIX+ Provider Communication Training; Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Meningococcal Meningitis
Interventions: Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine; Biological
Lead sponsor: Novartis; Industry
Eligibility: 11 Years to 18 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 17
States / cities: Birmingham, Alabama • Fremont, California • Madera, California + 14 more

Conditions: Multiple Myeloma, Myeloma, Multiple, Myeloma-Multiple
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Infections, Meningococcal
Interventions: MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine; Combination Product · Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 50 Years
Enrollment: 1,440 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more

Conditions: Meningitis, Meningococcal Disease
Interventions: None administered in this study; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 62,626 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Oakland, California

Search by objective public record fields.

Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Safety of 4CMenB Exposure During Pregnancy

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

High and Low Resource Interventions to Promote HPV Vaccines

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Study of the Immune Response After Vaccination in Multiple Myeloma Patients

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine